Mural Oncology (NASDAQ:MURA) Rating Lowered to Equal Weight at Morgan Stanley

Morgan Stanley downgraded shares of Mural Oncology (NASDAQ:MURA) from an overweight rating to an equal weight rating in a research report released on Tuesday morning, MarketBeat reports.

A number of other research analysts have also weighed in on the company. HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Mural Oncology in a research note on Wednesday, March 12th. Raymond James downgraded Mural Oncology from a “strong-buy” rating to an “outperform” rating and set a $18.00 target price on the stock. in a research report on Tuesday. Finally, Jones Trading restated a “hold” rating on shares of Mural Oncology in a report on Tuesday. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $16.00.

Mural Oncology Trading Down 61.6 %

Mural Oncology stock opened at $1.47 on Tuesday. The stock has a 50-day moving average price of $3.87 and a 200 day moving average price of $3.61. Mural Oncology has a 52 week low of $1.37 and a 52 week high of $5.12. The stock has a market cap of $25.33 million, a PE ratio of -0.16 and a beta of 3.66.

Mural Oncology (NASDAQ:MURA) last issued its quarterly earnings results on Tuesday, March 11th. The company reported ($2.01) EPS for the quarter, missing analysts’ consensus estimates of ($1.96) by ($0.05). During the same period last year, the firm posted ($3.57) EPS. On average, equities analysts predict that Mural Oncology will post -7.54 EPS for the current year.

Hedge Funds Weigh In On Mural Oncology

Several hedge funds and other institutional investors have recently modified their holdings of the company. Commerce Bank purchased a new position in Mural Oncology in the third quarter valued at approximately $39,000. FMR LLC raised its stake in shares of Mural Oncology by 124.7% in the 3rd quarter. FMR LLC now owns 20,580 shares of the company’s stock valued at $64,000 after acquiring an additional 11,423 shares during the period. Point72 Asset Management L.P. purchased a new position in shares of Mural Oncology in the 3rd quarter valued at $340,000. Geode Capital Management LLC lifted its holdings in shares of Mural Oncology by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 190,056 shares of the company’s stock valued at $595,000 after acquiring an additional 4,731 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in Mural Oncology during the 4th quarter worth $181,000. 80.21% of the stock is owned by institutional investors and hedge funds.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.